{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:03:38Z","timestamp":1790013818533,"version":"4.0.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>BRD4 (\u201cBromodomain-containing protein 4\u201d), a recognized gene regulator, is an attractive target for therapeutic development, particularly for the management of neuroblastoma. An integrated pharmacoinformatic strategy for the development of new BRD4 inhibitors is examined in this research. Pharmacophores were used to digitally screen five databases, and the current study aims to determine the best binding modes by docking the screened hits to the BRD4 active site. Using the BRD4 protein co-crystal ligand (73B) (PDB ID: 4BJX) as a template, pharmacophore hypotheses were produced. Five databases were subjected to a pharmacophore-based virtual screening process, and 1089 hits that satisfied the screening requirements were selected for docking against the BRD4 receptor by using the SP module of the Glide tool. The top ten docked compounds with the highest binding affinities, ranging from \u2212\u20099.623 to \u2212 8.894\u00a0kcal\/mol, were selected. Further, the biological activity and ADMET analysis revealed that the selected compounds have values that fall in the acceptable range. The protein-ligand complexes\u2019 stability was verified by performing molecular dynamics (MD) simulations of the binding positions of the top two compounds against the BRD4 receptor. The stability and binding free energies of the compounds indicate that these compounds may function as lead compounds to affect the biological activity of BRD4 in the in vitro studies.<\/jats:p>","DOI":"10.1038\/s41598-025-20714-2","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:30:49Z","timestamp":1761125449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Computational discovery of BRD4 inhibitors for neuroblastoma therapy using pharmacophore screening and molecular simulations"],"prefix":"10.1038","volume":"15","author":[{"given":"Iqra","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervt","family":"Almostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faheem","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy S.","family":"Younis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azmat Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galal","family":"Yahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"issue":"1","key":"20714_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10555-020-09946-y","volume":"40","author":"IS Fetahu","year":"2021","unstructured":"Fetahu, I. S. & Taschner-Mandl, S. Neuroblastoma and the epigenome. Cancer Metastasis Rev. 40 (1), 173\u2013189 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"20714_CR2","doi-asserted-by":"publisher","first-page":"773186","DOI":"10.3389\/fonc.2021.773186","volume":"11","author":"Y Gao","year":"2022","unstructured":"Gao, Y. et al. Synergistic anti-tumor effect of combining selective CDK7 and BRD4 Inhibition in neuroblastoma. Front. Oncol. 11, 773186 (2022).","journal-title":"Front. Oncol."},{"issue":"6","key":"20714_CR3","first-page":"2503","volume":"53","author":"Y Tan","year":"2018","unstructured":"Tan, Y. et al. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression. Int. J. Oncol. 53 (6), 2503\u20132517 (2018).","journal-title":"Int. J. Oncol."},{"issue":"5","key":"20714_CR4","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1159\/000472407","volume":"41","author":"X Wu","year":"2017","unstructured":"Wu, X. et al. Inhibition of BRD4 suppresses cell proliferation and induces apoptosis in renal cell carcinoma. Cell. Physiol. Biochem. 41 (5), 1947\u20131956 (2017).","journal-title":"Cell. Physiol. Biochem."},{"key":"20714_CR5","doi-asserted-by":"publisher","first-page":"103415","DOI":"10.1016\/j.jprot.2019.103415","volume":"205","author":"Y Zhao","year":"2019","unstructured":"Zhao, Y. et al. Pharmacoproteomics reveal novel protective activity of bromodomain containing 4 inhibitors on vascular homeostasis in TLR3-mediated airway remodeling. J. Proteom. 205, 103415 (2019).","journal-title":"J. Proteom."},{"issue":"1","key":"20714_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1165\/rcmb.2017-0445OC","volume":"60","author":"B Tian","year":"2019","unstructured":"Tian, B. et al. Efficacy of novel highly specific bromodomain-containing protein 4 inhibitors in innate inflammation\u2013driven airway remodeling. Am. J. Respir. Cell Mol. Biol. 60 (1), 68\u201383 (2019).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"6","key":"20714_CR7","doi-asserted-by":"publisher","first-page":"L1183","DOI":"10.1152\/ajplung.00224.2016","volume":"311","author":"B Tian","year":"2016","unstructured":"Tian, B. et al. BRD4 mediates NF-\u03baB-dependent epithelial-mesenchymal transition and pulmonary fibrosis via transcriptional elongation. Am. J. Physiology-Lung Cell. Mol. Physiol. 311 (6), L1183\u2013L1201 (2016).","journal-title":"Am. J. Physiology-Lung Cell. Mol. Physiol."},{"issue":"23","key":"20714_CR8","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1091\/mbc.e09-05-0380","volume":"20","author":"A Dey","year":"2009","unstructured":"Dey, A. et al. Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol. Biol. Cell. 20 (23), 4899\u20134909 (2009).","journal-title":"Mol. Biol. Cell"},{"issue":"17","key":"20714_CR9","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1128\/.20.17.6537-6549.2000","volume":"20","author":"A Dey","year":"2000","unstructured":"Dey, A. et al. A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G2-to-M transition. Mol. Cell. Biol. 20 (17), 6537\u20136549 (2000).","journal-title":"Mol. Cell. Biol."},{"issue":"11","key":"20714_CR10","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1021\/acs.jmedchem.6b01761","volume":"60","author":"Z Liu","year":"2017","unstructured":"Liu, Z. et al. Drug discovery targeting bromodomain-containing protein 4. J. Med. Chem. 60 (11), 4533\u20134558 (2017).","journal-title":"J. Med. Chem."},{"issue":"2","key":"20714_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ccr.2014.01.028","volume":"25","author":"J Shi","year":"2014","unstructured":"Shi, J. et al. Disrupting the interaction of BRD4 with diacetylated twist suppresses tumorigenesis in basal-like breast cancer. Cancer cell. 25 (2), 210\u2013225 (2014).","journal-title":"Cancer cell."},{"issue":"1","key":"20714_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.drudis.2019.11.002","volume":"25","author":"AR Brasier","year":"2020","unstructured":"Brasier, A. R. & Zhou, J. Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling. Drug Discovery Today. 25 (1), 126\u2013132 (2020).","journal-title":"Drug Discovery Today"},{"issue":"11","key":"20714_CR13","doi-asserted-by":"publisher","first-page":"01880","DOI":"10.1128\/jvi","volume":"94","author":"E Alamer","year":"2020","unstructured":"Alamer, E. et al. Epigenetic suppression of HIV in myeloid cells by the BRD4-selective small molecule modulator ZL0580. J. Virol. 94 (11), 01880\u201301819. https:\/\/doi.org\/10.1128\/jvi (2020).","journal-title":"J. Virol."},{"issue":"5","key":"20714_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrd4286","volume":"13","author":"P Filippakopoulos","year":"2014","unstructured":"Filippakopoulos, P. & Knapp, S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discovery. 13 (5), 337\u2013356 (2014).","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"8","key":"20714_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","volume":"18","author":"AG Cochran","year":"2019","unstructured":"Cochran, A. G., Conery, A. R. & Sims, R. J. Bromodomains: a new target class for drug development. Nat. Rev. Drug Discovery. 18 (8), 609\u2013628 (2019).","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"7","key":"20714_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrd.2017.125","volume":"16","author":"M Cully","year":"2017","unstructured":"Cully, M. BET inhibitor attenuates heart failure. Nat. Rev. Drug Discovery. 16 (7), 453\u2013453 (2017).","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"7327","key":"20714_CR17","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos, P. et al. Selective Inhibition of BET bromodomains. Nature 468 (7327), 1067\u20131073 (2010).","journal-title":"Nature"},{"issue":"3","key":"20714_CR18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3892\/ijo.2017.4081","volume":"51","author":"J Hao","year":"2017","unstructured":"Hao, J. et al. Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K\/AKT pathway. Int. J. Oncol. 51 (3), 823\u2013831 (2017).","journal-title":"Int. J. Oncol."},{"issue":"5","key":"20714_CR19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/1535-7163.MCT-15-0567","volume":"15","author":"HK Bid","year":"2016","unstructured":"Bid, H. K. et al. The bromodomain BET inhibitor JQ1 suppresses tumor angiogenesis in models of childhood sarcoma. Mol. Cancer Ther. 15 (5), 1018\u20131028 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"20714_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12038-016-9600-6","volume":"41","author":"B Padmanabhan","year":"2016","unstructured":"Padmanabhan, B. et al. Bromodomain and extra-terminal (BET) family proteins: new therapeutic targets in major diseases. J. Biosci. 41, 295\u2013311 (2016).","journal-title":"J. Biosci."},{"issue":"7","key":"20714_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrc3256","volume":"12","author":"AC Belkina","year":"2012","unstructured":"Belkina, A. C. & Denis, G. V. BET domain co-regulators in obesity, inflammation and cancer. Nat. Rev. Cancer. 12 (7), 465\u2013477 (2012).","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"20714_CR22","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.chembiol.2014.07.003","volume":"21","author":"CM Chiang","year":"2014","unstructured":"Chiang, C. M. Nonequivalent response to bromodomain-targeting BET inhibitors in oligodendrocyte cell fate decision. Chem. Biol. 21 (7), 804\u2013806 (2014).","journal-title":"Chem. Biol."},{"key":"20714_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ejmech.2018.04.006","volume":"151","author":"Z Liu","year":"2018","unstructured":"Liu, Z. et al. Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. Eur. J. Med. Chem. 151, 450\u2013461 (2018).","journal-title":"Eur. J. Med. Chem."},{"issue":"21","key":"20714_CR24","doi-asserted-by":"publisher","first-page":"11657","DOI":"10.1080\/07391102.2023.2170471","volume":"41","author":"M Er-Rajy","year":"2023","unstructured":"Er-Rajy, M. et al. Design of novel anti-cancer drugs targeting TRKs inhibitors based 3D QSAR, molecular Docking and molecular dynamics simulation. J. Biomol. Struct. Dynamics. 41 (21), 11657\u201311670 (2023).","journal-title":"J. Biomol. Struct. Dynamics"},{"issue":"1","key":"20714_CR25","doi-asserted-by":"publisher","first-page":"101911","DOI":"10.1016\/j.jsps.2023.101911","volume":"32","author":"M Aloui","year":"2024","unstructured":"Aloui, M. et al. QSAR modelling, molecular docking, molecular dynamic and ADMET prediction of pyrrolopyrimidine derivatives as novel bruton\u2019s tyrosine kinase (BTK) inhibitors. Saudi Pharm. J. 32 (1), 101911 (2024).","journal-title":"Saudi Pharm. J."},{"key":"20714_CR26","doi-asserted-by":"publisher","first-page":"101911","DOI":"10.1016\/j.jsps.2023.101911","volume":"32","author":"M Aloui","year":"2024","unstructured":"Aloui, M. et al. QSAR modelling, molecular docking, molecular dynamic and ADMET prediction of pyrrolopyrimidine derivatives as novel bruton\u2019s tyrosine kinase (BTK) inhibitors. Saudi Pharm. J. ; 32: 101911. (2024).","journal-title":"Saudi Pharm. J."},{"issue":"3","key":"20714_CR27","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s11224-022-01913-3","volume":"33","author":"M Er-rajy","year":"2022","unstructured":"Er-rajy, M. et al. 2D-QSAR modeling, drug-likeness studies, ADMET prediction, and molecular Docking for anti-lung cancer activity of 3-substituted-5-(phenylamino) Indolone derivatives. Struct. Chem. 33 (3), 973\u2013986 (2022).","journal-title":"Struct. Chem."},{"issue":"10","key":"20714_CR28","doi-asserted-by":"publisher","first-page":"105193","DOI":"10.1016\/j.arabjc.2023.105193","volume":"16","author":"M Er-rajy","year":"2023","unstructured":"Er-rajy, M. et al. Design of novel anti-cancer agents targeting COX-2 inhibitors based on computational studies. Arab. J. Chem. 16 (10), 105193 (2023).","journal-title":"Arab. J. Chem."},{"issue":"2","key":"20714_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/CAD.0000000000001492","volume":"35","author":"M Er-Rajy","year":"2024","unstructured":"Er-Rajy, M. et al. Design of potential anti-cancer agents as COX-2 inhibitors, using 3D-QSAR modeling, molecular docking, oral bioavailability proprieties, and molecular dynamics simulation. Anti-Cancer Drugs. 35 (2), 117\u2013128 (2024).","journal-title":"Anti-Cancer Drugs"},{"key":"20714_CR30","doi-asserted-by":"crossref","unstructured":"Rudrapal, M., Khairnar, S. J. & Jadhav, A. G. Drug repurposing (DR): an emerging approach in drug discovery. Drug repurposing-hypothesis, molecular aspects and therapeutic applications, 10. (2020).","DOI":"10.5772\/intechopen.93193"},{"key":"20714_CR31","doi-asserted-by":"publisher","first-page":"137473","DOI":"10.1016\/j.molstruc.2023.137473","volume":"1302","author":"FA Ugbe","year":"2024","unstructured":"Ugbe, F. A. et al. Computational evaluation of the inhibitory potential of some urea, thiourea, and Selenourea derivatives of diselenides against leishmaniasis: 2D-QSAR, pharmacokinetics, molecular docking, and molecular dynamics simulation. J. Mol. Struct. 1302, 137473 (2024).","journal-title":"J. Mol. Struct."},{"issue":"1","key":"20714_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s44371-024-00025-7","volume":"1","author":"EI Edache","year":"2024","unstructured":"Edache, E. I. et al. Drug-like screening, molecular docking, molecular dynamics simulations, and binding free energies on the interaction of pyrazole derivatives as inhibitors of lysosomal storage disorders and anticancer activity. Discover Chem. 1 (1), 22 (2024).","journal-title":"Discover Chem."},{"key":"20714_CR33","doi-asserted-by":"crossref","unstructured":"Edache, E. I. et al. DFT studies on structure, electronics, bonding nature, NBO analysis, thermodynamic properties, molecular docking, and MM-GBSA evaluation of 4-methyl-3-[2-(4-nitrophenyl)-1, 3-dioxo-2, 3-dihydro-1 H-isoindole-5-amido] benzoic acid: a potent inhibitor of Graves\u2019 disease. J. Umm Al-Qura Univ. Appl. Sci. 1\u201319. (2024).","DOI":"10.1007\/s43994-024-00132-2"},{"issue":"3","key":"20714_CR34","first-page":"346","volume":"2","author":"EI Edache","year":"2024","unstructured":"Edache, E. I. et al. Evaluation of novel Anti-SARS-CoV-2 compounds by targeting nucleoprotein and envelope protein through homology modeling, Docking simulations, ADMET, and molecular dynamic simulations with the MM\/GBSA calculation. Intell. Pharm. 2 (3), 346\u2013366 (2024).","journal-title":"Intell. Pharm."},{"key":"20714_CR35","doi-asserted-by":"crossref","unstructured":"Naqvi, A. A. et al. Advancements in Docking and molecular dynamics simulations towards ligand-receptor interactions and structure-function relationships. Curr. Top. Med. Chem. 18(20): pp. 1755\u20131768. (2018).","DOI":"10.2174\/1568026618666181025114157"},{"issue":"W1","key":"20714_CR36","first-page":"W442","volume":"44","author":"J Sunseri","year":"2016","unstructured":"Sunseri, J. D.R.J.N.a.r. Koes. Pharmit: Interact. Explor. Chem. Space. 44 (W1), W442\u2013W448 (2016).","journal-title":"Pharmit: Interact. Explor. Chem. Space"},{"key":"20714_CR37","doi-asserted-by":"crossref","unstructured":"Prabitha, P. et al. Multi-conformational frame from molecular dynamics as a structure-based pharmacophore model for mapping, screening and identifying ligands against PPAR-\u03b3: a new protocol to develop promising candidates. J. Biomol. Struct. Dyn. 40(6) 2663\u20132673. (2022).","DOI":"10.1080\/07391102.2020.1841677"},{"key":"20714_CR38","unstructured":"Oduselu, G. O., Ajani, O. O. & Ajamma, Y. U. Structure-Based drug design in discovering target specific drugs against plasmodium falciparum adenylosuccinate lyase. (2021)."},{"key":"20714_CR39","unstructured":"LigPrep, L. P. Schr\u00f6dinger, LLC. (2018)."},{"key":"20714_CR40","doi-asserted-by":"crossref","unstructured":"Shivakumar, D. et al. Improving the prediction of absolute solvation free energies using the next generation OPLS force field. J. Chem. Theory Comput. 8(8): pp. 2553\u20132558. (2012).","DOI":"10.1021\/ct300203w"},{"key":"20714_CR41","unstructured":"Schr\u00f6dinger, L. J. S. S. Schr\u00f6dinger, LLC; New York, NY: 2017. 2: pp. 2017\u20131. (2017)."},{"key":"20714_CR42","doi-asserted-by":"crossref","unstructured":"Kim, M. O. et al. Effects of histidine protonation and rotameric States on virtual screening of M. tuberculosis RmlC. J. Comput.-aided Mol. Des. 27(3): pp. 235\u2013246. (2013).","DOI":"10.1007\/s10822-013-9643-9"},{"key":"20714_CR43","doi-asserted-by":"crossref","unstructured":"Friesner, R. A. et al. Glide: a new approach for rapid, accurate Docking and scoring. 1. Method and assessment of Docking accuracy. J. Med. Chem. 47(7): pp. 1739\u20131749. (2004).","DOI":"10.1021\/jm0306430"},{"issue":"1","key":"20714_CR44","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7 (1), 42717 (2017).","journal-title":"Sci. Rep."},{"issue":"2","key":"20714_CR45","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1021\/ci500588j","volume":"55","author":"T Sander","year":"2015","unstructured":"Sander, T. et al. DataWarrior: an open-source program for chemistry aware data visualization and analysis. J. Chem. Inf. Model. 55 (2), 460\u2013473 (2015).","journal-title":"J. Chem. Inf. Model."},{"key":"20714_CR46","doi-asserted-by":"crossref","unstructured":"Mali, SN. & Chaudhari, H.K. Computational studies on imidazo [1, 2-a] pyridine-3-carboxamide analogues as antimycobacterial agents: Common pharmacophore generation, atom-based 3D-QSAR, molecular dynamics simulation, QikProp, molecular docking and prime MMGBSA approaches. Open Pharma. Sci. J. 5(1). (2018).","DOI":"10.2174\/1874844901805010012"},{"issue":"5","key":"20714_CR47","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden, S. & Ryde, U. The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov. 10 (5), 449\u2013461 (2015).","journal-title":"Expert Opin. Drug Discov."},{"issue":"11","key":"20714_CR48","doi-asserted-by":"publisher","first-page":"e0294511","DOI":"10.1371\/journal.pone.0294511","volume":"18","author":"I Ali","year":"2023","unstructured":"Ali, I. et al. Computational exploration of novel ROCK2 inhibitors for cardiovascular disease management; insights from high-throughput virtual screening, molecular docking, DFT and MD simulation. Plos One. 18 (11), e0294511 (2023).","journal-title":"Plos One"},{"key":"20714_CR49","doi-asserted-by":"crossref","unstructured":"Bowers, K. J. et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. in Proceedings of the ACM\/IEEE Conference on Supercomputing (2006).","DOI":"10.1145\/1188455.1188544"},{"key":"20714_CR50","doi-asserted-by":"crossref","unstructured":"Price, D. J. & C.L.J .T.J.o.c.p. Brooks III, A modified TIP3P water potential for simulation with Ewald summation. J. Chem. Phys. 121(20), 10096\u201310103. (2004).","DOI":"10.1063\/1.1808117"},{"key":"20714_CR51","doi-asserted-by":"crossref","unstructured":"Mir, I. H. et al. Elucidation of Escitalopram oxalate and related antidepressants as putative inhibitors of PTP4A3\/PRL-3 protein in hepatocellular carcinoma: A multi-computational investigation. Comput. Biol. Chem. 108039. (2024).","DOI":"10.1016\/j.compbiolchem.2024.108039"},{"key":"20714_CR52","doi-asserted-by":"crossref","unstructured":"Thillainayagam, M. et al. In-Silico molecular docking and simulation studies on novel chalcone and flavone hybrid derivatives with 1, 2, 3-triazole linkage as vital inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biomol. Struct. Dyn. 36(15), 3993\u20134009. (2018).","DOI":"10.1080\/07391102.2017.1404935"},{"key":"20714_CR53","doi-asserted-by":"publisher","first-page":"1163197","DOI":"10.3389\/fvets.2023.1163197","volume":"10","author":"S Lata","year":"2023","unstructured":"Lata, S. et al. The study of structure and effects of two new proanthocyanidins from anogeissus pendula leaves on rumen enzyme activities. Front. Veterinary Sci. 10, 1163197 (2023).","journal-title":"Front. Veterinary Sci."},{"key":"20714_CR54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12154-017-0167-y","volume":"10","author":"T Khan","year":"2017","unstructured":"Khan, T. et al. Molecular docking, PASS analysis, bioactivity score prediction, synthesis, characterization and biological activity evaluation of a functionalized 2-butanone thiosemicarbazone ligand and its complexes. J. Chem. Biol. 10, 91\u2013104 (2017).","journal-title":"J. Chem. Biol."},{"issue":"4","key":"20714_CR55","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/wics.1310","volume":"6","author":"SC Chow","year":"2014","unstructured":"Chow, S. C. Bioavailability and bioequivalence in drug development. Wiley Interdisciplinary Reviews: Comput. Stat. 6 (4), 304\u2013312 (2014).","journal-title":"Wiley Interdisciplinary Reviews: Comput. Stat."},{"key":"20714_CR56","doi-asserted-by":"crossref","unstructured":"Godschalk, F. et al. Comparison of MM\/GBSA calculations based on explicit and implicit solvent simulations. Phys. Chem. Chem. Phys. 15(20): pp. 7731\u20137739. (2013).","DOI":"10.1039\/c3cp00116d"},{"issue":"23","key":"20714_CR57","first-page":"12788","volume":"120","author":"S Decherchi","year":"2020","unstructured":"Decherchi, S. & Cavalli, A. J. C. R. Thermodyn. Kinetics drug-target Binding Mol. Simul. 120(23): 12788\u201312833. (2020).","journal-title":"Thermodyn. Kinetics drug-target Binding Mol. Simul."},{"key":"20714_CR58","doi-asserted-by":"crossref","unstructured":"Sargsyan, K. et al. How molecular size impacts RMSD applications in molecular dynamics simulations. J. Chem. Theory Comput. 13(4): pp. 1518\u20131524. (2017).","DOI":"10.1021\/acs.jctc.7b00028"},{"key":"20714_CR59","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez, L. J. P. Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis.PloS one 10(3): p. e0119264. (2015).","DOI":"10.1371\/journal.pone.0119264"},{"issue":"24","key":"20714_CR60","doi-asserted-by":"publisher","first-page":"13830","DOI":"10.1080\/07391102.2023.2279269","volume":"42","author":"FA Ugbe","year":"2024","unstructured":"Ugbe, F. A. et al. Cheminformatics-based discovery of new organoselenium compounds with potential for the treatment of cutaneous and visceral leishmaniasis. J. Biomol. Struct. Dynamics. 42 (24), 13830\u201313853 (2024).","journal-title":"J. Biomol. Struct. Dynamics"},{"issue":"1","key":"20714_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s44371-024-00026-6","volume":"1","author":"FA Ugbe","year":"2024","unstructured":"Ugbe, F. A. et al. Cheminformatic evaluation of the multi-protein binding potential of some diselenide derivatives: A plausible drug discovery approach for leishmaniasis. Discover Chem. 1 (1), 25 (2024).","journal-title":"Discover Chem."},{"key":"20714_CR62","doi-asserted-by":"crossref","unstructured":"Ullah, S. et al. Identification of lead compound screened from the natural products atlas to treat renal inflammasomes using molecular Docking and dynamics simulation. J. Biomol. Struct. Dynamics, 1\u201311. (2023).","DOI":"10.1080\/07391102.2023.2254397"},{"issue":"11","key":"20714_CR63","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1002\/jcb.26064","volume":"118","author":"D Thirumal Kumar","year":"2017","unstructured":"Thirumal Kumar, D. et al. A molecular Docking and dynamics approach to screen potent inhibitors against fosfomycin resistant enzyme in clinical Klebsiella pneumoniae. J. Cell. Biochem. 118 (11), 4088\u20134094 (2017).","journal-title":"J. Cell. Biochem."},{"key":"20714_CR64","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s10930-020-09953-6","volume":"40","author":"V Dalal","year":"2021","unstructured":"Dalal, V. et al. Structure-based identification of potential drugs against FmtA of Staphylococcus aureus: virtual screening, molecular dynamics, MM-GBSA, and QM\/MM. Protein. J. 40, 148\u2013165 (2021).","journal-title":"Protein. J."},{"issue":"3","key":"20714_CR65","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/biomedicines11030793","volume":"11","author":"I Ali","year":"2023","unstructured":"Ali, I. et al. Identification of natural lead compounds against hemagglutinin-esterase surface glycoprotein in human coronaviruses investigated via MD simulation, principal component analysis, cross-correlation, H-bond plot and MMGBSA. Biomedicines 11 (3), 793 (2023).","journal-title":"Biomedicines"},{"key":"20714_CR66","doi-asserted-by":"publisher","first-page":"1003816","DOI":"10.3389\/fchem.2022.1003816","volume":"10","author":"N Ashraf","year":"2022","unstructured":"Ashraf, N. et al. Combined 3D-QSAR, molecular Docking and dynamics simulations studies to model and design TTK inhibitors. Front. Chem. 10, 1003816 (2022).","journal-title":"Front. Chem."},{"key":"20714_CR67","doi-asserted-by":"publisher","first-page":"112426","DOI":"10.1016\/j.ejmech.2020.112426","volume":"200","author":"D Liang","year":"2020","unstructured":"Liang, D., Yu, Y. & Ma, Z. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery. Eur. J. Med. Chem. 200, 112426 (2020).","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"20714_CR68","doi-asserted-by":"publisher","first-page":"749","DOI":"10.18596\/jotcsa.927426","volume":"8","author":"MT Muhammed","year":"2021","unstructured":"Muhammed, M. T. & Esin, A. Y. Pharmacophore modeling in drug discovery: methodology and current status. J. Turkish Chem. Soc. Sect. A: Chem. 8 (3), 749\u2013762 (2021).","journal-title":"J. Turkish Chem. Soc. Sect. A: Chem."},{"issue":"4","key":"20714_CR69","doi-asserted-by":"publisher","first-page":"270","DOI":"10.2174\/1574893615666191219094216","volume":"15","author":"R Jakhar","year":"2020","unstructured":"Jakhar, R. et al. Relevance of molecular Docking studies in drug designing. Curr. Bioinform. 15 (4), 270\u2013278 (2020).","journal-title":"Curr. Bioinform."},{"issue":"1","key":"20714_CR70","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.drudis.2019.10.014","volume":"25","author":"CY Jia","year":"2020","unstructured":"Jia, C. Y. et al. A drug-likeness toolbox facilitates ADMET study in drug discovery. Drug Discovery Today. 25 (1), 248\u2013258 (2020).","journal-title":"Drug Discovery Today"},{"issue":"1","key":"20714_CR71","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/pr9010071","volume":"9","author":"OM Salo-Ahen","year":"2020","unstructured":"Salo-Ahen, O. M. et al. Molecular dynamics simulations in drug discovery and pharmaceutical development. Processes 9 (1), 71 (2020).","journal-title":"Processes"},{"issue":"4","key":"20714_CR72","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/jmr.836","volume":"20","author":"S Bobrovnik","year":"2007","unstructured":"Bobrovnik, S. The influence of rigid or flexible linkage between two ligands on the effective affinity and avidity for reversible interactions with bivalent receptors. J. Mol. Recognition: Interdisciplinary J. 20 (4), 253\u2013262 (2007).","journal-title":"J. Mol. Recognition: Interdisciplinary J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20714-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20714-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20714-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T11:02:32Z","timestamp":1761130952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20714-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["20714"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-20714-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36850"}}